ADC Therapeutics (ADCT) News Today → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free ADCT Stock Alerts $3.42 -0.06 (-1.72%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 3, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanJune 2, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Sees Significant Growth in Short InterestADC Therapeutics SA (NYSE:ADCT - Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 1,000,000 shares, an increase of 16.6% from the April 30th total of 857,600 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 566,800 shares, the days-to-cover ratio is currently 1.8 days.June 2, 2024 | americanbankingnews.comADC Therapeutics SA (NYSE:ADCT) Receives $7.25 Average Price Target from BrokeragesMay 31, 2024 | americanbankingnews.comADC Therapeutics (NYSE:ADCT) Coverage Initiated by Analysts at Cantor FitzgeraldMay 30, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by BrokeragesADC Therapeutics SA (NYSE:ADCT - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recomMay 30, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns Overweight Rating from Analysts at Cantor FitzgeraldCantor Fitzgerald initiated coverage on ADC Therapeutics in a report on Thursday. They issued an "overweight" rating for the company.May 30, 2024 | globenewswire.comADC Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 15, 2024 | globenewswire.comADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | finance.yahoo.comADC Therapeutics First Quarter 2024 Earnings: In Line With ExpectationsMay 10, 2024 | insidertrades.comAmeet Mallik Sells 29,731 Shares of ADC Therapeutics SA (NYSE:ADCT) StockMay 9, 2024 | marketbeat.comInsider Selling: ADC Therapeutics SA (NYSE:ADCT) CEO Sells 29,731 Shares of StockADC Therapeutics SA (NYSE:ADCT - Get Free Report) CEO Ameet Mallik sold 29,731 shares of the stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $4.48, for a total transaction of $133,194.88. Following the completion of the sale, the chief executive officer now owns 1,167,348 shares of the company's stock, valued at approximately $5,229,719.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.May 9, 2024 | finance.yahoo.comInsider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)May 9, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 9, 2024 | globenewswire.comADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Zynlonta Clinical Data and Strategic Growth OutlookMay 7, 2024 | finance.yahoo.comADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comHC Wainwright Cuts ADC Therapeutics (NYSE:ADCT) Price Target to $8.00HC Wainwright dropped their price target on ADC Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday.May 7, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings ResultsADC Therapeutics (NYSE:ADCT - Get Free Report) released its earnings results on Monday. The company reported ($0.56) EPS for the quarter, meeting the consensus estimate of ($0.56). ADC Therapeutics had a negative net margin of 344.15% and a negative return on equity of 1,313.37%. During the same quarter in the previous year, the company posted ($0.74) earnings per share.May 6, 2024 | finanznachrichten.deADC Therapeutics SA: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsMay 6, 2024 | finance.yahoo.comADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsMay 6, 2024 | investorplace.comADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 6, 2024 | globenewswire.comADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaMay 2, 2024 | marketbeat.comADC Therapeutics (ADCT) Set to Announce Earnings on MondayADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Monday, May 6, Zacks reports.May 1, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMay 1, 2024 | finance.yahoo.comADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024April 30, 2024 | seekingalpha.comADCT ADC Therapeutics SAApril 18, 2024 | marketbeat.comHC Wainwright Comments on ADC Therapeutics SA's Q1 2024 Earnings (NYSE:ADCT)ADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at HC Wainwright cut their Q1 2024 earnings per share estimates for shares of ADC Therapeutics in a research note issued on Monday, April 15th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.56) per shaApril 16, 2024 | marketbeat.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 5.7%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 993,100 shares, a growth of 5.7% from the March 15th total of 939,800 shares. Based on an average daily trading volume, of 791,000 shares, the short-interest ratio is presently 1.3 days. Currently, 1.8% of the shares of the company are short sold.April 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial ProgressApril 15, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT)HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of ADC Therapeutics in a report on Monday.April 5, 2024 | marketbeat.comADC Therapeutics' (ADCT) "Buy" Rating Reiterated at GuggenheimGuggenheim reissued a "buy" rating on shares of ADC Therapeutics in a research note on Friday.April 4, 2024 | msn.comADC Therapeutics gains after data for lymphoma therapyApril 4, 2024 | globenewswire.comADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaApril 3, 2024 | globenewswire.comADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024April 1, 2024 | finance.yahoo.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanMarch 28, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from BrokeragesShares of ADC Therapeutics SA (NYSE:ADCT - Get Free Report) have been assigned a consensus rating of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recomMarch 28, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns Buy Rating from Analysts at GuggenheimGuggenheim began coverage on shares of ADC Therapeutics in a research report on Thursday. They set a "buy" rating and a $11.00 price target on the stock.March 18, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $8.00 price target on shares of ADC Therapeutics in a report on Thursday.March 16, 2024 | finance.yahoo.comUS$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These ResultsMarch 15, 2024 | seekingalpha.comADC Therapeutics SA (ADCT) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comQ4 2023 ADC Therapeutics SA Earnings CallMarch 13, 2024 | finance.yahoo.comADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic ResetMarch 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | marketbeat.comTrading was temporarily halted for "ADCT" at 09:03 AM with a stated reason of "LULD pause."March 13, 2024 | globenewswire.comADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 6, 2024 | globenewswire.comADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitMarch 6, 2024 | globenewswire.comADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Was the Great Financial Crisis fun? (Ad)The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, was terrible! The majority of market indexes lost over 50% of their value. Almost every day, traders would look at their trading accounts and just see a sea of red. Get those kind of results during the Great Financial Crisis, without having to study more ADCT Media Mentions By Week ADCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼0.490.73▲Average Medical News Sentiment ADCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼32▲ADCT Articles Average Week Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRSN News CCCC News NKTR News ALEC News VERV News CTMX News ITOS News DAWN News ABCL News LQDA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ADCT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored